Verve Therapeutics Inc. (VERV)
5.25
-0.25 (-4.55%)
At close: Jan 14, 2025, 3:59 PM
5.18
-1.29%
After-hours Jan 14, 2025, 07:07 PM EST
undefined% (undefined)
| Bid | 5.18 |
| Market Cap | 444.48M |
| Revenue (ttm) | - |
| Net Income (ttm) | - |
| EPS (ttm) | -2.45 |
| PE Ratio (ttm) | -2.14 |
| Forward PE | n/a |
| Analyst | Buy |
| Ask | 5.69 |
| Volume | 871,462 |
| Avg. Volume (20D) | 1,490,816 |
| Open | 5.59 |
| Previous Close | 5.50 |
| Day's Range | 5.19 - 5.67 |
| 52-Week Range | 4.30 - 19.34 |
| Beta | undefined |
About VERV
Verve Therapeutics, Inc., a genetic medicines company, engages in developing gene editing medicines for patients to treat cardiovascular diseases. Its lead product candidate is VERVE-101, a single-course gene editing treatment that permanently turns off the PCSK9 gene in the liver. The company also engages in the development of ANGPTL3 program to permanently turn off the ANGPTL3 gene in the liver. It has a collaboration and license agreement with...
Industry Biotechnology
Sector Healthcare
IPO Date Jun 17, 2021
Employees 255
Stock Exchange NASDAQ
Ticker Symbol VERV
Website https://www.vervetx.com
Analyst Forecast
According to 4 analyst ratings, the average rating for VERV stock is "Buy." The 12-month stock price forecast is $24.5, which is an increase of 366.67% from the latest price.
Buy 100.00%
Hold 0.00%
Sell 0.00%
Next Earnings Release
Verve Therapeutics Inc. is scheduled to release its earnings on Feb 25, 2025,
before market opens.
Analysts project revenue of $4.94M, reflecting a -3.95% YoY shrinking and earnings per share of -0.67, making a -2.90% decrease YoY.
Analysts project revenue of $4.94M, reflecting a -3.95% YoY shrinking and earnings per share of -0.67, making a -2.90% decrease YoY.
9 months ago ·
Source
-34.95%
Verve Therapeutics shares are trading lower amid t...
Unlock content with
Pro Subscription
10 months ago ·
Source
+21.47%
Verve Therapeutics shares are trading higher after the company reported better-than-expected Q4 financial results.
